Joe Duffy.pdf

More documents

Recommendations

Info

uPA: Transfer to Clinic • Clinical value must be validated in a gold-standard or level I evidence study
LOE for Grading Clinical utility of Tumor Markers • I. High powered randomized prospective trial or meta/pooled analysis • II. Therapeutic trial to test therapeutic hypothesis but not marker utility • III. Large retrospective study • IV. Small retrospective study • V. Pilot study Hayes et al JNCI 1996;88:1456
Page 1 and 2: Breast Cancer Metastasis: Biomarker
Page 3 and 4: Most Important Questions After a Di
Page 5 and 6: Node-Negative Breast Cancer: Treatm
Page 7 and 8: ADJUVANT CHEMOTHERAPY FOR BREAST CA
Page 9 and 10: QUESTION Should most node-negative
Page 11 and 12: Invasion & Metastasis Invasive Carc
Page 13 and 14: uPA in Breast Cancer • We showed
Page 15: uPA as Prognostic Markers in Breast
Page 19 and 20: Participating laboratories (9 count
Page 21 and 22: STRATIFICATION RANDOMISATION Prospe
Page 23 and 24: uPA in Breast Cancer: Implication o
Page 25 and 26: uPA for Determining Prognosis in Br
Page 27: Acknowledgements • HRB • Irish

Joe Duffy.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?